Evidence map›Paper›PMID 38755413›Full record

ArticleWorld journal of microbiology & biotechnology2024

Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.

Safaa Altves, Ebru Guclu, Esra Yetisgin, Kivanc Bilecen, Hasibe Vural

Abstract read
In one paragraph

Article in World journal of microbiology & biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Safaa AltvesDepartment of Medical Biology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. safaa.e.t@gmail.com.ORCID http://orcid.org/0000-0001-5873-2085
Ebru GucluDepartment of Basic Science and Health, Hemp Research Institute, Yozgat Bozok University, Yozgat, Turkey.ORCID http://orcid.org/0000-0001-5330-6159
Esra YetisginDepartment of Molecular Biology & Genetics, Faculty of Agriculture and Natural Sciences, Konya Food and Agriculture University, Safaa ALTVES, Konya, Turkey.ORCID http://orcid.org/0000-0001-8606-4424
Kivanc BilecenDepartment of Molecular Biology & Genetics, Faculty of Agriculture and Natural Sciences, Konya Food and Agriculture University, Safaa ALTVES, Konya, Turkey.ORCID http://orcid.org/0000-0002-6254-3516
Hasibe VuralDepartment of Medical Biology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.ORCID http://orcid.org/0000-0003-2564-7807

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally colorectal cancer ranks as the third most widespread disease and the third leading cause of cancer-associated mortality. Immunotherapy treatments like PD-L1 blockade have been used to inhibit the PD-L1 legend, which boosts the activity of cytotoxic T lymphocytes. Recently, studies suggest that some probiotics could potentially enhance the effectiveness of immunotherapy treatments for cancer patients. We found that in Caco-2 and HT-29 cells, the live Leuconostoc mesenteroides treatment resulted an increase in the PD-L1 expression and this treatment stimulated interferon-gamma (IFN-γ) production in Jurkat T-cells. Due to the well-established ability of IFN-γ to enhance PD-L1 expression, the combination of IFN-γ and L. mesenteroides was used in colon cancer cell lines and a resulting remarkable increase of over tenfold in PD-L1 expression was obtained. Interestingly, when L. mesenteroides and IFN-γ are present, the blockage of PD-L1 using PD-L1 antibodies not only improved the viability of Jurkat T-cells but also significantly boosted the levels of IFN-γ and IL-2, the T-cells activation marker cytokines. In addition to upregulating PD-L1, L. mesenteroides also activated Toll-like receptors (TLRs) and NOD-like receptors (NODs) pathways, specifically through TLR2 and NOD2, while also exerting a suppressive effect on autophagy in colon cancer cell lines. In conclusion, our findings demonstrate a significant upregulation of PD-L1 expression in colon cancer cells upon co-culturing with L. mesenteroides. Moreover, the presence of PD-L1 antibodies during co-culturing activates Jurkat T cells. The observed enhancement in PD-L1 expression may be attributed to the inhibition of the Autophagy pathway or activation of the hippo pathway. KEY POINTS: Co-culturing L. mesenteroides increases PD-L1 gene and protein transaction in colon cancer. L. mesenteroides existing enhances T cells viability and activity. GPCR41/42 is a possible link between L. mesenteroides, YAP-1 and PD-L1.

Indexed as

B7-H1 AntigenColonic NeoplasmsInterferon-gammaLeuconostoc mesenteroidesT-LymphocytesCaco-2 CellsCell Line, TumorHT29 CellsHumansInterleukin-2Jurkat CellsLymphocyte ActivationNod2 Signaling Adaptor ProteinProbioticsToll-Like Receptor 2Up-RegulationB7-H1 AntigenCD274 protein, humanInterferon-gammaInterleukin-2NOD2 protein, humanNod2 Signaling Adaptor ProteinToll-Like Receptor 2ImmunotherapyLeuconostoc mesenteroidesPD-L1Probiotic

Identifiers

PMID38755413
PMCPMC11098917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.